LifeStyle

3Novices:Novartis Secures European Approval Cancer Treatment

By Martin Baccardax
Novartis AG said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AG’s blockbuster Rituxan that generated around US$7.5 billion in sales last year. 

Sandoz, the biosimilar division of Swiss drugmaker Novartis, said the approval allows for the use of Rixathon in Europe and represents a “big win” for patients with “blood cancers or immunological…
June 19, 2017 at 01:30PM http://ift.tt/2shieTd
#3Novices #News #OnlineMedia #China #LifeStyle 3Novices China

Advertisements
Standard

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s